Detection of trastuzumab efficacy using ¹H MRI ex vivo of breast cancer cells

Download
  1. Get@NRC: Detection of trastuzumab efficacy using ¹H MRI ex vivo of breast cancer cells (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1007/s00044-011-9759-1
AuthorSearch for: ; Search for:
TypeArticle
Journal titleMedicinal Chemistry Research
ISSN1054-2523
1554-8120
Volume21
Issue9
Pages23162319; # of pages: 4
Subjectmagnetic resonance imaging; breast cancer cells; drug efficacy
AbstractThis study is aimed on Magnetic resonance imaging (MRI) modalities for monitoring Herceptin (trastuzumab) efficacy in breast cancer cells ex vivo. The efficacy profile of trastuzumab (0.010 μg/ml) was examined using T2 relaxivity measurements prior to and after 24, 48, and 72 h treatment. The untreated MCF-7 cells were considered as a control. MRI results show early tumor response to treatment while comparing pre- and post-treatment T2. The changes of T2 MRI correspond to tumor growth inhibition. The study shows that MRI can be used for the non-invasive monitoring of cancer cells’ death caused by immuno-targeting in preclinical testing of efficacy and treatment regimens.
Publication date
LanguageEnglish
AffiliationNRC Institute for Biodiagnostics; National Research Council Canada
Peer reviewedYes
Identifier9759
NPARC number21268252
Export citationExport as RIS
Report a correctionReport a correction
Record identifierd7d49b8e-ab2a-4267-846a-c6753bd9dda6
Record created2013-06-10
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)